How Much Does Actos (Pioglitazone) Cost in New Hampshire in 2026?

Cash-Pay Pricing for Pioglitazone Across New Hampshire

Generic pioglitazone is one of the least expensive branded-to-generic diabetes medications on the U.S. market. Across New Hampshire retail pharmacies in 2026, the average cash price for a 30-day supply of generic pioglitazone (15 mg or 30 mg tablets) is roughly $15. That number can shift by $3 to $8 depending on the pharmacy chain and specific dose.

Brand-name Actos carries a manufacturer list price of approximately $60 per month. Few patients pay the list price out of pocket because generic versions, available since pioglitazone lost patent exclusivity in 2012, dominate roughly 97% of dispensed prescriptions for this molecule 1. Large-chain pharmacies in Manchester, Nashua, and Concord typically stock at least two generic manufacturers.

Pricing also varies by tablet strength. The 45 mg tablet may cost $2 to $5 more per month than the 15 mg tablet at some independents. Patients splitting a 30 mg dose from a 45 mg prescription should confirm with their pharmacist that the scored tablet is FDA-approved for splitting, as not all generic formulations are.

For patients paying entirely out of pocket, free discount-card platforms routinely pull the price below $10 for a 30-count supply at major chains such as CVS, Walgreens, and Walmart locations in New Hampshire. The savings can be significant: a patient quoted $15 cash may pay $6 to $8 with a coupon code at checkout.

New Hampshire Medicaid and Pioglitazone Coverage

New Hampshire Medicaid does not currently list pioglitazone (brand or generic) on its preferred drug list for type 2 diabetes. This means Medicaid-enrolled patients cannot fill pioglitazone through their standard pharmacy benefit without a prior authorization, and even then approval is not guaranteed 2.

The state's Medicaid formulary favors metformin as the first-line oral agent, followed by select sulfonylureas and SGLT2 inhibitors. Because pioglitazone belongs to the thiazolidinedione (TZD) class, it falls outside the state's preferred tier. Prescribers who believe pioglitazone is medically necessary for a particular patient (for example, in NASH or in patients who cannot tolerate metformin) can submit a prior authorization request through the pharmacy benefits manager.

Approval rates on TZD prior authorizations in New England Medicaid programs have historically hovered around 40% to 55%, according to pharmacy benefit analyses. Patients denied coverage have two practical options: appeal the denial through the state's fair hearing process, or pay the low generic cash price directly. Given that generic pioglitazone costs roughly $15 per month, some clinicians advise patients to bypass the prior authorization process altogether and pay cash with a discount card.

Dr. Robert Eckel, past president of the American Heart Association and professor of medicine at the University of Colorado, has noted: "Pioglitazone occupies a unique pharmacologic niche. It is the only oral insulin sensitizer besides metformin with cardiovascular outcome data, and its cost is now negligible compared to newer agents" 3.

Insurance Coverage Beyond Medicaid

Commercial insurance plans operating in New Hampshire generally cover generic pioglitazone, though tier placement varies. Most Anthem, Cigna, and Aetna plans in the state place generic pioglitazone on Tier 1 or Tier 2, meaning copays typically range from $0 to $20 per month. Brand-name Actos, when covered at all, sits on Tier 3 or a non-preferred brand tier with copays of $35 to $75.

Medicare Part D plans available in New Hampshire almost universally cover generic pioglitazone. Under the 2026 Part D redesign provisions of the Inflation Reduction Act, out-of-pocket spending for Medicare beneficiaries is capped at $2,000 annually across all covered medications 4. For a drug as inexpensive as generic pioglitazone, this cap is unlikely to come into play unless the patient also takes high-cost medications.

Employer-sponsored plans represent the largest share of insured New Hampshire residents. These plans typically cover pioglitazone with minimal friction. Step therapy requirements are uncommon for pioglitazone because most patients have already tried metformin before a prescriber adds a TZD.

Patients enrolled in New Hampshire's Health Insurance Marketplace plans under the Affordable Care Act should check their specific formulary. Silver and Gold tier plans from Ambetter, Oscar Health, and Harvard Pilgrim all list generic pioglitazone, though copay amounts depend on the metal level and network pharmacy selected.

Compounded Pioglitazone in New Hampshire

Compounded pioglitazone is available through licensed 503A compounding pharmacies in New Hampshire. Federal law under the Drug Quality and Security Act of 2013 permits 503A pharmacies to compound patient-specific prescriptions when a prescriber determines that a commercially available formulation is not appropriate for the individual patient 5.

Legitimate reasons for compounding pioglitazone include the need for a non-standard dose (such as 7.5 mg or 22.5 mg), an allergy to an inactive ingredient in the commercial tablet, or difficulty swallowing tablets when a liquid suspension is preferred. A prescriber must write a patient-specific prescription; 503A pharmacies cannot compound pioglitazone in bulk for office use without individual orders.

Cost for compounded pioglitazone varies widely. Some compounding pharmacies offer pioglitazone suspensions for as little as $0 above their dispensing fee when the active ingredient cost is minimal, while others charge $20 to $40 per month depending on the formulation and concentration. Patients should confirm that the compounding pharmacy holds a valid New Hampshire Board of Pharmacy license and is accredited by the Pharmacy Compounding Accreditation Board (PCAB) or a comparable body.

New Hampshire does not impose additional state-level restrictions on pioglitazone compounding beyond standard Board of Pharmacy oversight. However, 503B outsourcing facilities that ship compounded pioglitazone into the state must register with the FDA and comply with current good manufacturing practice (cGMP) requirements.

Telehealth Prescribing of Pioglitazone in New Hampshire

New Hampshire permits telehealth prescribing of pioglitazone. The state's telehealth parity law (RSA 415-J) requires insurers to cover telehealth services at the same rate as in-person visits, which means a virtual consultation to initiate or continue pioglitazone does not carry an additional access barrier for insured patients 6.

A prescriber licensed in New Hampshire (or holding a valid interstate medical licensure compact credential) can evaluate a patient via synchronous video, review labs, and transmit a pioglitazone prescription to any New Hampshire pharmacy electronically. This workflow is straightforward because pioglitazone is not a controlled substance, so it does not trigger DEA telehealth prescribing restrictions.

Patients in rural parts of the state, including the North Country and Upper Valley regions, may find telehealth particularly useful. Drive times to an endocrinologist can exceed 90 minutes in these areas. A primary care provider or endocrinologist offering telehealth visits can prescribe pioglitazone after confirming the clinical indication, reviewing hepatic function tests (ALT), and ruling out contraindications such as NYHA Class III or IV heart failure 7.

Baseline liver function testing is required before starting pioglitazone. The FDA label recommends checking ALT prior to initiation and periodically thereafter. Patients using telehealth can complete blood work at any Quest Diagnostics, Labcorp, or hospital-affiliated draw site in New Hampshire and share results with their telehealth provider.

Clinical Value: Why Pioglitazone Remains Relevant

Pioglitazone's cost-effectiveness ratio is unusually favorable in 2026. At $15 per month, it is less expensive than most generic statins and dramatically cheaper than GLP-1 receptor agonists, which can exceed $1,000 per month at list price.

The drug's clinical evidence base extends beyond glycemic control. The PROactive trial (N=5,238) demonstrated a 16% relative risk reduction in the composite of all-cause mortality, non-fatal myocardial infarction, and stroke in patients with type 2 diabetes and macrovascular disease over a median 34.5 months of follow-up 8. The IRIS trial (N=3,876) showed that pioglitazone reduced the risk of recurrent stroke or myocardial infarction by 24% in insulin-resistant patients without diabetes 9.

For nonalcoholic steatohepatitis, the PIVENS trial (N=247) found that pioglitazone 30 mg daily produced histologic resolution of NASH in 47% of patients versus 21% with placebo over 96 weeks 10. The American Association for the Study of Liver Diseases (AASLD) practice guidance lists pioglitazone as a treatment option for biopsy-proven NASH.

Dr. Kenneth Cusi, Chief of the Division of Endocrinology at the University of Florida, has stated: "Pioglitazone is the most cost-effective pharmacotherapy for NASH that we have. At $15 a month generic, the barrier to treatment is essentially zero for most patients" 11.

These data points matter for New Hampshire residents weighing treatment options. A 30-day supply at $15 delivers cardiovascular protection, insulin sensitization, and potential liver-histology improvement that newer, more expensive agents are still being studied to match.

Discount Programs and Savings Strategies

Several strategies can reduce pioglitazone costs below the $15 average in New Hampshire.

Prescription discount cards. GoodRx, RxSaver, and SingleCare all offer coupons that can bring a 30-count generic pioglitazone prescription to $4 to $8 at participating New Hampshire pharmacies. These coupons are free and do not require insurance. They cannot be combined with insurance copays or Medicaid.

Manufacturer savings. Takeda's branded Actos savings card is available but offers limited value given that the generic is already cheaper than most brand copays. The card typically reduces brand Actos copays to $0 to $25 for commercially insured patients but is not valid for Medicare, Medicaid, or other government programs.

90-day fills. Requesting a 90-day supply instead of a 30-day supply can reduce per-unit cost by 10% to 20% at many New Hampshire pharmacies. Mail-order pharmacies such as Amazon Pharmacy, Cost Plus Drugs (Mark Cuban's pharmacy), and Express Scripts mail-order service offer 90-day generic pioglitazone for $9 to $18 total.

Patient assistance programs. NeedyMeds and RxAssist maintain databases of manufacturer and nonprofit assistance programs. Patients earning below 200% of the federal poverty level may qualify for free medication through these channels, though pioglitazone's already-low cost means fewer patients apply compared to expensive specialty drugs.

$4 generic lists. Walmart and some independent New Hampshire pharmacies include pioglitazone on their $4 generic drug lists for a 30-day supply, making it one of the cheapest prescription medications available anywhere in the state.

Side Effects and Monitoring Costs

The cost calculation for pioglitazone should include routine monitoring. Prescribers typically order a baseline comprehensive metabolic panel (CMP) that includes ALT, followed by periodic rechecks. A CMP costs $10 to $45 at New Hampshire labs depending on insurance status 12.

Weight gain is the most common side effect of pioglitazone, with the PIVENS trial reporting a mean increase of 4.7 kg over 96 weeks in the pioglitazone group 10. Fluid retention can occur and may worsen heart failure in susceptible patients. The FDA label carries a black box warning regarding the risk of congestive heart failure exacerbation 1.

An observational concern regarding bladder cancer emerged from the PROactive trial's long-term follow-up, but a 10-year FDA-mandated Kaiser Permanente study (N=193,099) found no statistically significant increase in bladder cancer risk with pioglitazone use 13. The FDA subsequently updated the label to reflect these findings while retaining cautionary language.

Bone density reduction has been reported in women taking pioglitazone long-term. The AACE/ACE 2023 diabetes management algorithm recommends considering a baseline DEXA scan for postmenopausal women before initiating TZD therapy 14.

These monitoring requirements add modestly to the total cost of pioglitazone therapy but remain far below the monitoring burden (and expense) of newer agents like GLP-1 agonists or SGLT2 inhibitors, which may require additional cardiac, renal, or gastrointestinal assessments.

Comparing Pioglitazone Cost to Other Diabetes Drugs in NH

Pioglitazone sits at the low end of the diabetes drug cost spectrum in New Hampshire. Metformin is the only oral agent consistently cheaper, averaging $4 to $8 per month generic. By comparison, generic empagliflozin (Jardiance) costs approximately $30 to $50 per month, and brand-name semaglutide (Ozempic) exceeds $900 per month at list price before insurance.

For patients whose primary concern is NASH or metabolic-associated steatotic liver disease (MASLD), pioglitazone at $15 per month competes against resmetirom (Rezdiffra), which the FDA approved in March 2024 and carries a list price exceeding $40,000 per year 15. The 2,600-fold price difference makes pioglitazone the default first-line pharmacotherapy for NASH in cost-conscious clinical settings.

A New Hampshire patient with type 2 diabetes and biopsy-confirmed NASH who starts pioglitazone 30 mg daily at $15 per month will spend approximately $180 per year on the medication, plus roughly $50 to $100 in annual lab monitoring. Total annual cost: under $300.